FIELD: medicine.
SUBSTANCE: group of inventions concerns medicine, namely, to oncology and can be used for treatment of the cancer expressing intergrin α5β1. The ways under the invention include introduction of the liquid pharmaceutical composition containing 0.1-15 mg/ml of an antibody against α5β1 to the patient.
EFFECT: possibility to suppress proliferation and to prevent diffusion of a tumour at the expense of direct lysis of cancer cells at fixation by an intergrin α5β1 antibody on their surface.
22 cl, 2 dwg, 6 tbl, 9 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CHIMERIC AND HUMANISED INTEGRIN α5β1 ANTIBODIES MODULATING ANGIOGENESIS | 2003 |
|
RU2346701C2 |
| SUPPRESSION OF CANCER METASTASES | 2010 |
|
RU2571502C2 |
| COMBINED THERAPY BY USING ANTIANGIOGENIC AGENTS AND TNF-ALPHA | 2002 |
|
RU2316337C2 |
| NOVEL ANTIBODIES | 2008 |
|
RU2490277C2 |
| ALPHA5-BETA 1 ANTIBODIES AND USING THEM | 2009 |
|
RU2528736C2 |
| NEW SYNERGETIC EFFECTS | 2009 |
|
RU2471499C2 |
| VERSIONS OF DISINTEGRIN AND THEIR PHARMACEUTICAL APPLICATION | 2015 |
|
RU2685869C1 |
| METHODS FOR TREATMENT OF METASTATIC CANCER TYPES, USING AXL TRAP RECEPTORS | 2018 |
|
RU2785866C2 |
| COMBINED THERAPY USING INHIBITORS OF TYROSINE KINASE RECEPTORS AND INHIBITORS OF ANGIOGENESIS | 2001 |
|
RU2292904C2 |
| CONTROL POINT INHIBITOR AND WHOLE MYCOBACTERIAL CELLS FOR USE IN CANCER THERAPY | 2016 |
|
RU2733033C2 |
